Park­er In­sti­tute backs an up­start biotech look­ing to de­vel­op a new, con­vert­ible CAR-T

The bil­lion­aire-backed Park­er In­sti­tute for Can­cer Im­munother­a­py is in­vest­ing and part­ner­ing with a biotech their re­searchers be­lieve has the po­ten­tial to de­vel­op a new-mod­el CAR-T that can be bet­ter guid­ed down nar­row path­ways and equipped with a con­ve­nient on/off switch to help avoid any fa­tal ac­ci­dents.

Park­er CEO Jef­frey Blue­stone isn’t giv­ing away any num­bers right now, but he says the in­sti­tute’s eq­ui­ty in­vest­ment in Xyphos Bio­sciences “isn’t triv­ial.” The pri­ma­ry pur­pose of the in­vest­ment — and the re­search al­liance that plugs Xyphos in­to their net­work of promi­nent in­ves­ti­ga­tors — is to ac­cel­er­ate the work and pre­vent it from get­ting stuck in the R&D mud.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.